Tempest Therapeutics, Inc. (TPST): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Financial and Accounting Officer On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therape
How this was made
The 30-second read
Why it matters
The change could influence the company's financial reporting quality and future capital market activities.
Market read
Executive turnover is a material corporate action for investors but unlikely to cause major price moves absent further guidance.
What to watch
Potential hidden restructuring or strategic shifts not disclosed in the filing.
Background
Tempest Therapeutics filed a Form 8‑K announcing CFO departure and new appointment, a standard corporate governance disclosure.
Ticker impact
SEC 8‑K reports resignation of CFO Justin Trojanowski and appointment of Nicholas Rossettos as new CFO, effective Sep 1 2026.
Potential short‑term volatility; no clear directional bias.
Executive turnover is material for a biotech but does not imply immediate operational change.
Market effects
May prompt analysts to reassess TPST's financial guidance and fundraising capability.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond investors tracking small‑cap biotech stocks.
Counterpoint
New CFO's extensive biotech finance experience could accelerate upcoming financing rounds, offering upside.
Key entities
- companyTempest Therapeutics, Inc.
Biotech firm listed on Nasdaq under TPST.
- personJustin Trojanowski
Outgoing Principal Financial and Accounting Officer.
- personNicholas Rossettos
Incoming CFO, Principal Financial and Accounting Officer.
